| |
|
|
|
GlobalCompliancePanel, Online Training
2012-03-07
Overview: This webinar will examine the existing and proposed requirements for the FDA's DHF -- including its derivative documents, the DMR and DHR.
It will consider the MDD's TF/DD requirements, and evaluate the documents' differing purposes / goals. Required and desirable contents will be discussed. Also considered: Areas requiring frequent re-evaluation / update; Similarities and differences; Future trends; Typical DHF Table of Contents; Technical File or Design Dossier Table of Contents; The importance and usefulness of the "Essential Requirements"; Structure of the "Declaration of Conformity"; self-declaring or N-B reviewed; Parallel approaches to development. Finally, the differing approaches to file audits by the FDA and the Notified Body will be discussed.
Why you should attend: One of our most popular webinars, updated with the latest FDA and EU requirements. As U.S. companies go global, they must meet different product design documentation. The cGMPs mandate Design Control and the Design History File (DHF). In order to sell globally, the EU's CE-marking documentation is a requirement -- the Technical File or Design Dossier. Currently they serve different purposes, support different goals, but the TF/DD is moving in the direction of the DHF. And the DHF is adapting to some of the features of the TF/DD. And how / where do the DMR and DHR fit? Being aware of the similarities and differences can further concurrent development and/or updates to both.
Areas Covered in the Session:- The U.S. FDA's DHF
- The EU's MDD and the Technical File / Design Dossier
- Design Control vs. a Product 'Snapshot in Time'
- DHF "Typical" Contents
- The DMR and DHR / Lot / Batch Record
- TF / DD Expected Contents
- Parallel Approaches to Documentation -- Teams
- Future Directions
- FDA and NB Audit Focus
Who Will Benefit:- Senior management in Drugs, Devices, Biologics, Dietary Supplements
- QA
- RA
- R&D
- Engineering
- Production
- Operations
- Marketing
|
|
|
|
|
|
|
|
Organized by:
|
|
GlobalCompliancePanel |
|
|
Invited Speakers:
|
|
John E. Lincoln is a medical device and regulatory affairs consultant. He has helped companies to implement or modify their GMP systems and procedures, product risk management, U.S. FDA responses. In addition, he has successfully designed, written and run all types of process, equipment and software qualifications/validations, which have passed FDA audit or submission scrutiny, and described in peer-reviewed technical articles, and workshops, world wide. John has also managed pilot production, regulatory affairs, product development/design control, 510(k) submissions, risk management per ISO 14971, and projects; with over 28 years of experience in the FDA-regulated medical products industry - working with start-ups to Fortune 100 companies, including Abbott Laboratories, Hospira, Tyco/Mallinckrodt. He is a graduate of UCLA.
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2012-03-06
|
|
|
|
|
|
|
|
Registration:
|
|
Price List: Live : $245.00 Corporate live : $995.00 Recorded : $295.00
webinars@globalcompliancepanel.com http://www.globalcompliancepanel.com
Phone: 800-447-9407 Fax: 302-288-6884
1000 N West Street | Suite 1200 | Wilmington | DE | Zip 19801 | USA
|
|
|
E-mail:
|
|
globalcompliancepanel@gmail.com
|
|
|
|
|
|
|
|
|